Editorial: Considerations for Approval of Biosimilars

Biologics_mapAlcami recently contributed to a special feature in the August / September issue of Chemicals Knowledge magazine, titled "Considerations for Approval of Biosimilars."

Biosimilars are sometimes incorrectly considered equivalent to a generic small molecule therapeutic, but for a biologic drug product, the clinical and regulatory pathways are quite different. Alcami Commercial Development Manager Cheryl Johnson explains the distinct differences in the FDA’s definition, development strategy, and regulatory approval pathways.

Read Full Article Here




Ready to Get Started?

Connect with an Expert


Topics: Regulatory Compliance Biologics Editorials Parenteral Manufacturing